What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma

Costa, Bruno Almeida; Mouhieddine, Tarek H.; Richter, Joshua

doi:10.1007/s11523-022-00897-8

Cited by 7 publications

(4 citation statements)

References 232 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the 5-year relative survival rate for US patients diagnosed with MM increased from 28.6% in 1986-1993 to 57.9% in 2012-2018. 6,7 The therapeutic armamentarium continues to expand at an unprecedented pace. Particularly exciting is the recent approval of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies for relapsed and/or refractory MM (RRMM), advancements which may further enhance the long-term prognosis for individuals affected by this condition.…”

Section: Car T-cell Therapy For Multiple Myeloma: a Clinical Practice...mentioning

confidence: 99%

“…42 Despite scarce data in patients receiving CAR T-cell therapy for RRMM, bendamustine-based lymphodepletion could be a suitable option in certain subgroups (e.g., patients inserted in healthcare systems undergoing fludarabine shortage or with renal insufficiency). 43 As alternative LDC regimens are explored, strict rationing has been recommended in order to preserve the extremely limited supply of fludarabine. 41…”

Section: Preparing For Car T-cell Therapymentioning

confidence: 99%

“…In this scenario, off‐label use of bendamustine (90 mg per m 2 of body‐surface area for 2 days) has been deemed safe and effective before tisagenlecleucel infusion among patients with large BCL 42 . Despite scarce data in patients receiving CAR T‐cell therapy for RRMM, bendamustine‐based lymphodepletion could be a suitable option in certain subgroups (e.g., patients inserted in healthcare systems undergoing fludarabine shortage or with renal insufficiency) 43 . As alternative LDC regimens are explored, strict rationing has been recommended in order to preserve the extremely limited supply of fludarabine 41 …”

Section: Preparing For Car T‐cell Therapymentioning

confidence: 99%

“…The advent of anti‐myeloma therapies, such as immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies (mAbs) has had a transformative impact on patient outcomes. For instance, the 5‐year relative survival rate for US patients diagnosed with MM increased from 28.6% in 1986–1993 to 57.9% in 2012–2018 6,7 . The therapeutic armamentarium continues to expand at an unprecedented pace.…”

mentioning

confidence: 99%

See 3 more Smart Citations

CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

Sadek,

Costa,

Nath

et al. 2023

Clin Pharma and Therapeutics

Self Cite

View full text Add to dashboard Cite

The emergence of chimeric antigen receptor (CAR) T‐cell therapy has revolutionized the treatment of hematologic malignancies, including multiple myeloma (MM). Two B‐cell maturation antigen (BCMA)‐directed CAR T‐cell products — idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) — have received Food and Drug Administration (FDA) approval for patients with relapsed/refractory MM who underwent four or more prior lines of therapy (including an immunomodulatory agent, a proteasome inhibitor, and an anti‐CD38 monoclonal antibody). Despite producing unprecedented response rates in an otherwise difficult to treat patient population, CAR T‐cell therapies are commonly associated with immune‐related adverse events (e.g., cytokine release syndrome and neurotoxicity), cytopenias and infections. Moreover, many patients continue to exhibit relapse post‐treatment, with resistance mechanisms yet to be fully understood. Ongoing basic, translational, and clinical research efforts are poised to generate deeper insights into the optimal utilization of these therapies, improve their efficacy, minimize associated toxicity, and identify new target antigens in MM patients.

show abstract

Section: Car T-cell Therapy For Multiple Myeloma: a Clinical Practice...mentioning

confidence: 99%